A RAS Renaissance: Emerging Targeted Therapies for KRAS-Mutated Non–Small Cell Lung Cancer

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Clinical Cancer Research

• Publication date

  2014-06-03

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-13-1762PMID 24893629PMCID PMC5369356
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Faculty Opinions recommendation of K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions.

  2013cited by this paper
• Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling

  2013cited by this paper
• Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.

  2013influential reference
• Phase I dose escalation study of the PKC&igr; inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer

  2013cited by this paper
• K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

  2013cited by this paper
• Phase I dose escalation study of the protein kinase C iota inhibitor aurothiomalate for advanced non-small cell lung cancer, ovarian cancer, and pancreatic cancer.

  2013influential reference
• Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models.

  2013cited by this paper
• A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

  2012influential reference
• Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation.

  2012cited by this paper
• ASSOCIATION BETWEEN TUMOR EGFR AND KRAS MUTATION STATUS AND CLINICAL OUTCOMES IN NSCLC PATIENTS RANDOMIZED TO SORAFENIB PLUS BEST SUPPORTIVE CARE ( BSC ) OR BSC ALONE : SUBANALYSIS OF THE PHASE III MISSION TRIAL

  2012cited by this paper
• Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.

  2012cited by this paper
• The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins

  2012cited by this paper
• Breast cancer, early stage

  2012cited by this paper
• RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally

  2012cited by this paper
• Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity

  2012cited by this paper
• The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer.

  2012cited by this paper
• Abstract 4163: Determination of synthetic lethal interactions in KRAS oncogene dependent cancer cells reveals novel therapeutic targeting strategies

  2012cited by this paper
• Antitumor Activity of a Novel Oncrasin Analogue Is Mediated by JNK Activation and STAT3 Inhibition

  2011cited by this paper
• TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation.

  2011cited by this paper
• RAS oncogenes: weaving a tumorigenic web

  2011cited by this paper
• The BATTLE trial: personalizing therapy for lung cancer.

  2011cited by this paper
• The GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins

  2011influential reference
• An Orthosteric Inhibitor of the Ras-Sos Interaction

  2011cited by this paper
• Searching for synthetic lethality in cancer.

  2011cited by this paper
• Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress

  2011cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-cell lung cancer.

  2011influential reference
• Therapeutic strategies for targeting ras proteins.

  2011cited by this paper
• A Phase II Trial of Salirasib in Patients with Lung Adenocarcinomas with KRAS Mutations

  2011cited by this paper
• Farnesyltransferase inhibitors: where are we now?

  2010cited by this paper
• A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma.

  2010cited by this paper
• MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.

  2010cited by this paper
• Stabilizing a weak binding state for effectors in the human ras protein by cyclen complexes.

  2010cited by this paper
• COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

  2010cited by this paper
• A Phase II, Open-Label, Randomized Study to Assess the Efficacy and Safety of AZD6244 (ARRY-142886) Versus Pemetrexed in Patients with Non-small Cell Lung Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens

  2010influential reference
• Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models.

  2010cited by this paper
• Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

  2009cited by this paper
• KRAS mutations in non-small cell lung cancer.

  2009influential reference
• First experimental identification of Ras-inhibitor binding interface using a water-soluble Ras ligand.

  2009cited by this paper
• A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene.

  2009cited by this paper
• Ras oncogenes: split personalities

  2008cited by this paper
• Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease.

  2008cited by this paper
• Inhibitors of chronically active ras: potential for treatment of human malignancies.

  2008cited by this paper
• Rce1 deficiency accelerates the development of K-RAS-induced myeloproliferative disease.

  2007cited by this paper
• Small-Molecule Inhibitors of the Rce1p CaaX Protease

  2007cited by this paper
• GEFs and GAPs: critical elements in the control of small G proteins.

  2007cited by this paper
• Lately, it occurs to me what a long, strange trip it's been for the farnesyltransferase inhibitors.

  2006influential reference
• RalB GTPase-Mediated Activation of the IκB Family Kinase TBK1 Couples Innate Immune Signaling to Tumor Cell Survival

  2006cited by this paper
• Faculty Opinions recommendation of RalB GTPase-mediated activation of the IkappaB family kinase TBK1 couples innate immune signaling to tumor cell survival.

  2006cited by this paper
• Compartmentalized Ras/MAPK signaling.

  2006cited by this paper
• Thematic review series: Lipid Posttranslational Modifications. Farnesyl transferase inhibitors Published, JLR Papers in Press, November 8, 2005.

  2006cited by this paper
• Lipid posttranslational modifications. Farnesyl transferase inhibitors.

  2006cited by this paper
• Targeting von Hippel-Lindau Pathway in Renal Cell Carcinoma

  2006cited by this paper
• Signaling interplay in Ras superfamily function.

  2005cited by this paper
• An oncogenic KRAS2 expression signature identified by cross-species gene-expression analysis

  2005cited by this paper
• Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib.

  2005cited by this paper
• Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.

  2005cited by this paper
• A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells.

  2005cited by this paper
• Farnesyltransferase inhibitor therapy in acute myelogenous leukemia.

  2005cited by this paper
• Inactivation of Icmt inhibits transformation by oncogenic K-Ras and B-Raf.

  2004cited by this paper
• Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer.

  2004cited by this paper
• Phase II study of the efficacy and tolerability of two dosing regimens of the farnesyl transferase inhibitor, R115777, in advanced breast cancer.

  2003cited by this paper
• Targeting RAS signalling pathways in cancer therapy

  2003cited by this paper
• Targeting Ras signaling through inhibition of carboxyl methylation: An unexpected property of methotrexate

  2003cited by this paper
• Searching for the elusive targets of farnesyltransferase inhibitors

  2003cited by this paper
• Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers

  2002cited by this paper
• Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.

  2002cited by this paper
• Absence of the CAAX Endoprotease Rce1: Effects on Cell Growth and Transformation

  2002cited by this paper
• A new functional Ras antagonist inhibits human pancreatic tumor growth in nude mice

  1999cited by this paper
• The pre-hydrolysis state of p21(ras) in complex with GTP: new insights into the role of water molecules in the GTP hydrolysis reaction of ras-like proteins.

  1999cited by this paper
• CaaX converting enzymes.

  1998influential reference
• Ki-ras mutations are an early event and correlate with tumor stage in transplacentally-induced murine lung tumors.

  1997cited by this paper
• K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors*

  1997cited by this paper
• Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

  1995cited by this paper
• A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane.

  1990cited by this paper
• The GTPase superfamily: a conserved switch for diverse cell functions

  1990cited by this paper
• Inhibition of purified p21ras farnesyl:protein transferase by Cys-AAX tetrapeptides.

  1990cited by this paper
• ras genes.

  1987cited by this paper
• Biological and biochemical properties of human rasH genes mutated at codon 61.

  1986cited by this paper
• Biological properties of human c-Ha-ras1 genes mutated at codon 12

  1984cited by this paper

• Evaluation of a Novel Pan-RAS Inhibitor in 3D Bioprinted Tumor Models

  2025cites this paper
• Mechanistic insights into molecular targeted therapy and immunotherapy for lung cancer.

  2025cites this paper
• Research progress of direct and indirect KRAS-targeting protein degraders in KRAS-mutant cancers.

  2025cites this paper
• ATR expression as a prognostic biomarker in KRAS-mutated non-small cell lung cancer

  2025cites this paper
• Comparison between sub-lobar resection and lobar resection for clinical stage IA (tumor size ≤ 2 cm) lung invasive mucinous adenocarcinoma with tumor spread through air spaces: A multi-center real-world study.

  2025cites this paper
• Potency and selectivity of a novel pan-RAS inhibitor in 3D bioprinted organoid tumor models

  2025cites this paper
• Current and Emerging Therapies for Targeting the ERK1/2 & PI3K Pathways in Cancer

  2025influential citation
• Chromosome aberrations cause tumorigenesis through chromosomal rearrangements in a hepatocarcinogenesis rat model

  2024cites this paper
• Development of erythrina-based PARP-1/FTase dual-target inhibitors against lung cancer epithelial-mesenchymal transition (EMT) in vivo and in vitro.

  2024cites this paper
• Comprehensive multimodal and multiomic profiling reveals epigenetic and transcriptional reprogramming in lung tumors

  2024cites this paper
• Circular RNAs in the KRAS pathway: Emerging players in cancer progression.

  2024cites this paper
• CASTOR1 phosphorylation predicts poor survival in male patients with KRAS-mutated lung adenocarcinoma

  2024cites this paper
• A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer

  2023cites this paper
• An Updated Review on KRAS Mutation in Lung Cancer (NSCLC) and Its Effects on Human Health

  2023cites this paper
• Biosensors for the detection of lung cancer biomarkers: A review on biomarkers, transducing techniques and recent graphene-based implementations.

  2023cites this paper
• The Next Generation of KRAS Targeting: Reasons for Excitement and Concern.

  2022cites this paper
• Targeting KRAS mutant cancers: from druggable therapy to drug resistance

  2022cites this paper
• Interactive, integrated analysis of single-cell transcriptomic and phylogenetic data with PhyloVision

  2022cites this paper
• Targeting KRAS G12C mutations in colorectal cancer

  2022cites this paper
• Inhibition of stearoyl-CoA desaturase 1 potentiates anti-tumor activity of amodiaquine in non-small cell lung cancer.

  2022cites this paper
• Enhancing an Oxidative “Trojan Horse” Action of Vitamin C with Arsenic Trioxide for Effective Suppression of KRAS-Mutant Cancers: A Promising Path at the Bedside

  2022cites this paper
• Targeting KRAS: Crossroads of Signaling and Immune Inhibition

  2022cites this paper
• Cholangiocarcinoma therapeutics: an update.

  2021cites this paper
• PhyloVision: Interactive Software for Integrated Analysis of Single-Cell Transcriptomic and Phylogenetic Data

  2021cites this paper
• Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma

  2021cites this paper
• Association of Exosomal miR-210 with Signaling Pathways Implicated in Lung Cancer

  2021cites this paper
• Mechanisms of Resistance to KRASG12C-Targeted Therapy.

  2021influential citation
• Diffuse expression of MUC6 defines a distinct clinicopathological subset of pulmonary invasive mucinous adenocarcinoma

  2020cites this paper
• The clinical impact of quantitative cell-free DNA, KRAS, and BRAF mutations on response to anti-EGFR treatment in patients with metastatic colorectal cancer.

  2020cites this paper
• mTOR in Lung Neoplasms

  2020cites this paper
• [Effects of farnesyltransferase silencing on the migration and invasion of tongue squamous cell carcinoma].

  2020cites this paper
• The Combination of Loss of ALDH1L1 Function and Phenformin Treatment Decreases Tumor Growth in KRAS-Driven Lung Cancer

  2020cites this paper
• Promising Molecular Targets for Design of Antitumor Drugs Based on Ras Protein Signaling Cascades

  2020cites this paper
• Inhibition of kras-derived exosomes downregulates immunosuppressive BACH2/GATA-3 expression via RIP-3 dependent necroptosis and miR-146/miR-210 modulation.

  2019cites this paper
• Mst1/2 kinases restrain transformation in a novel transgenic model of Ras driven non-small cell lung cancer

  2019cites this paper
• The Delta Subunit of Rod-Specific Photoreceptor cGMP Phosphodiesterase (PDE6D) Contributes to Hepatocellular Carcinoma Progression

  2019cites this paper
• From basic researches to new achievements in therapeutic strategies of KRAS-driven cancers

  2019cites this paper
• A three-dimensional cloth-based microfluidic label-free proximity hybridization-electrochemiluminescence biosensor for ultrasensitive detection of K-ras gene

  2019cites this paper
• Dual inhibition of GLUT1 and the ATR/CHK1 kinase axis displays synergistic cytotoxicity in KRAS-mutant cancer cells.

  2019cites this paper
• Treatment of Cancers by Inhibition of Isoprenylcysteine Carboxyl Methyltransferase.

  2019cites this paper
• KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition

  2019cites this paper
• miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway

  2018cites this paper
• An Ultrasensitive FRET-based DNA Sensor via the Accumulated QD System Derivatized in the Nano-beads

  2018cites this paper
• Role of chemokines in metastatic niche: new insights along with a diagnostic and prognostic approach

  2018cites this paper
• Double Trouble: A Case Series on Concomitant Genetic Aberrations in NSCLC

  2018cites this paper
• (3 + 3) Annulation of Nitroallylic Acetates with Stabilized Sulfur Ylides for the Synthesis of 2-Aryl Terephthalates.

  2018cites this paper
• Rethinking Gamma-secretase Inhibitors for Treatment of Non–small-Cell Lung Cancer: Is Notch the Target?

  2018cites this paper
• BET inhibition is an effective approach against KRAS-driven PDAC and NSCLC

  2018cites this paper
• mTOR mediates a mechanism of resistance to chemotherapy and defines a rational combination strategy to treat KRAS-mutant lung cancer

  2018cites this paper
• KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer.

  2018cites this paper
• Protein palmitoylation and cancer

  2018cites this paper
• Antitumor activity of sorafenib plus CDK4/6 inhibitor in pancreatic patient derived cell with KRAS mutation

  2018cites this paper
• Targeting PI3K pathway to enhance cisplatin cytotoxicity in lung cancer models

  2017cites this paper
• Clinicopathological and prognostic features of surgically resected pathological stage I lung adenocarcinoma harboring epidermal growth factor receptor and K‐ras mutation

  2017cites this paper
• Nature and Nurture: What Determines Tumor Metabolic Phenotypes?

  2017cites this paper
• Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells

  2017cites this paper
• Implications of farnesyltransferase and its inhibitors as a promising strategy for cancer therapy.

  2017cites this paper
• Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours

  2017cites this paper
• Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling.

  2017cites this paper
• Selumetinib for the treatment of non-small cell lung cancer

  2017cites this paper
• RAS oncogenes direct metastasis

  2017cites this paper
• New tricks for human farnesyltransferase inhibitor: cancer and beyond.

  2017cites this paper
• Adenocarcinoma of the lung: an exploration of the relationships between histopathology, molecular pathology and inflammatory markers and their relationship to patient outcomes

  2017cites this paper
• Metabolic Reprogramming of Pancreatic Ductal Adenocarcinoma Cells in Response to Chronic Low pH Stress

  2017cites this paper
• Clinicopathological, immunohistochemical, and mutational analyses of pulmonary enteric adenocarcinoma: usefulness of SATB2 and β-catenin immunostaining for differentiation from metastatic colorectal carcinoma.

  2017cites this paper
• Therapeutic Approaches of Non-Small Cell Lung Cancer (NSCLC) with KRAS Mutations

  2017influential citation
• Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.

  2016cites this paper
• Getting a Handle on RAS-targeted Therapies: Cysteine Directed Inhibitors.

  2016cites this paper
• Association Between Computed Tomographic Features and Kirsten Rat Sarcoma Viral Oncogene Mutations in Patients With Stage I Lung Adenocarcinoma and Their Prognostic Value.

  2016cites this paper
• Protein Kinase Cι Drives a NOTCH3-dependent Stem-like Phenotype in Mutant KRAS Lung Adenocarcinoma.

  2016cites this paper
• Independent and core pathways in oncogenic KRAS signaling

  2016cites this paper
• KRAS driven expression signature has prognostic power superior to mutation status in non‐small cell lung cancer

  2016cites this paper
• Autophagic degradation of epidermal growth factor receptor in gefitinib-resistant lung cancer by celastrol.

  2016cites this paper
• Non-small cell lung cancer biomarkers and targeted therapy - two faces of the same coin fostered by nanotechnology

  2016influential citation
• Correlation of Histologic Subtypes and Molecular Alterations in Pulmonary Adenocarcinoma: Therapeutic and Prognostic Implications

  2016cites this paper
• KIAA1522 is a novel prognostic biomarker in patients with non-small cell lung cancer

  2016cites this paper
• Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.

  2016cites this paper
• Kirsten Ras* oncogene: Significance of its discovery in human cancer research

  2016cites this paper
• Farnesyl transferase inhibitor FTI-277 inhibits breast cell invasion and migration by blocking H-Ras activation.

  2016cites this paper
• Discovery of Inhibitors of Protein–Protein Interactions Using Fragment‐Based Methods

  2016cites this paper
• Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers

  2016cites this paper
• Clinical outcome of epidermal growth factor receptor‐tyrosine kinase inhibitors therapy for patients with overlapping kirsten rat sarcoma 2 viral oncogene homolog and epidermal growth factor receptor gene mutations

  2015cites this paper
• The role of GSTP1 in KRAS induced lung tumorigenesis

  2015cites this paper
• Inducing Oncoprotein Degradation to Improve Targeted Cancer Therapy1

  2015cites this paper
• Conditional robustness analysis for fragility discovery and target identification in biochemical networks and in cancer systems biology

  2015cites this paper
• Precision Therapy for Lung Cancer: Tyrosine Kinase Inhibitors and Beyond.

  2015cites this paper
• RAS signaling and anti-RAS therapy: lessons learned from genetically engineered mouse models, human cancer cells, and patient-related studies.

  2015cites this paper
• Colorectal cancer-related mutant KRAS alleles function as positive regulators of autophagy

  2015cites this paper
• Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung

  2015cites this paper
• The Overexpression of FEN1 and RAD54B May Act as Independent Prognostic Factors of Lung Adenocarcinoma

  2015cites this paper
• Correction: Selective Targeting of CTNNB1-, KRAS- or MYC-Driven Cell Growth by Combinations of Existing Drugs

  2015cites this paper
• KRAS mutant lung cancer: progress thus far on an elusive therapeutic target

  2015influential citation
• Targeting lung cancer through inhibition of checkpoint kinases

  2015cites this paper
• Epiregulin as a therapeutic target in non-small-cell lung cancer

  2015influential citation
• EGFR and K-Ras mutations in women with lung adenocarcinoma: implications for treatment strategy definition

  2014cites this paper
• Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen

  2014cites this paper
• Molecular mechanisms of lung cancer

  year unknowncites this paper